Adhesion Assay

Simple SummaryContent extracted from patent full text and abstract with AI.

The invention provides a method and associated kits or devices for predicting whether a patient with inflammatory bowel disease (IBD) will respond to therapies that block the interaction between endothelial adhesion molecules (such as MAdCAM-1) and gut homing receptors (like integrin α4β7) on immune cells. This method involves flowing a patient's immune cells over a surface coated with these adhesion molecules and measuring how well the cells adhere, either untreated or after exposure to an inhibitor (e.g., vedolizumab). The test thus allows clinicians to determine, before starting therapy, whether a patient is likely to benefit from anti-adhesion drugs.

Use CasesContent extracted from patent full text and abstract with AI.

• Predicting clinical response of IBD patients to anti-adhesion therapies such as vedolizumab, natalizumab, etrolizumab, or SHP647 prior to treatment initiation.
• Screening candidate therapeutic compounds for their ability to inhibit immune cell adhesion relevant to IBD pathology.
• Personalizing treatment regimens in IBD by selecting only those patients likely to respond to specific anti-adhesion biological drugs, potentially saving costs and avoiding unnecessary side effects.
• Research into the mechanisms of leukocyte trafficking and adhesion in the gut, supporting development of new IBD therapies.
• Monitoring loss of drug response over time in patients already undergoing anti-adhesion therapy.

BenefitsContent extracted from patent full text and abstract with AI.

• Enables precision medicine by allowing tailored selection of IBD patients who will benefit from expensive and slowly-acting anti-adhesion therapies, potentially improving outcomes.
• Reduces unnecessary exposure to ineffective therapies for non-responders, minimizing side effects, disease progression, and health care costs.
• Facilitates rapid screening and validation of new drugs targeting cell adhesion mechanisms.
• Provides a functional assay using real patient cells, likely reflecting individual biological variability better than genetic or simple biomarker testing.
• Non-invasive, requires only blood samples, and can be implemented before or during different stages of treatment.
• Accelerates clinical decision-making and optimizes resource allocation in IBD management.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to a method for determining whether a patient with inflammatory bowel disease (IBD) will be responsive to an inhibitor of the interaction of endothelial adhesion molecules with gut homing receptors and kits for utilizing this method. In particular, the invention relates to a method for determining whether a patient with IBD is responsive to vedolizumab. The invention also encompasses a method for determining whether a candidate compound is suitable for the treatment of IBD.